REPAIR-HD

"Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington’s disease"

 Coordinatore CARDIFF UNIVERSITY 

 Organization address address: Newport Road 30-36
city: CARDIFF
postcode: CF24 ODE

contact info
Titolo: Dr.
Nome: Keith
Cognome: Sexton
Email: send email
Telefono: +44 2920 879288

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 7˙820˙107 €
 EC contributo 6˙000˙000 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2017-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    CARDIFF UNIVERSITY

 Organization address address: Newport Road 30-36
city: CARDIFF
postcode: CF24 ODE

contact info
Titolo: Dr.
Nome: Keith
Cognome: Sexton
Email: send email
Telefono: +44 2920 879288

UK (CARDIFF) coordinator 1˙906˙666.00
2    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Ms.
Nome: Laurie
Cognome: Louis-Joseph
Email: send email
Telefono: +33 1 45 17 29 32
Fax: +33 1 45 17 29 11

FR (PARIS) participant 926˙208.00
3    ROSLIN CELLS LIMITED

 Organization address address: "ROSLIN BIOCENTRE ROSLIN FOUNDATION, ROSLIN"
city: EDINBURGH
postcode: EH25 9PS

contact info
Titolo: Mrs.
Nome: Kathryn
Cognome: Reilly
Email: send email
Telefono: +44 131 658 5180

UK (EDINBURGH) participant 907˙408.00
4    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

 Organization address address: RUE LEBLANC 25
city: PARIS 15
postcode: 75015

contact info
Titolo: Dr.
Nome: Simone
Cognome: Mergui
Email: send email
Telefono: +33 1 46 54 93 64
Fax: +33 1 42 53 98 51

FR (PARIS 15) participant 721˙479.00
5    INSERM - TRANSFERT SA

 Organization address address: Rue Watt 7
city: PARIS
postcode: 75013

contact info
Titolo: Mr.
Nome: Louis
Cognome: Jammayrac
Email: send email
Telefono: +33 1 55 03 01 01
Fax: +33 1 55 03 01 60

FR (PARIS) participant 475˙056.00
6    GEORGE-HUNTINGTON-INSTITUT GMBH

 Organization address address: JOHANN KRANE WEG 27
city: MUNSTER
postcode: 48149

contact info
Titolo: Dr.
Nome: Ralf
Cognome: Reilmann
Email: send email
Telefono: +49 251 788 788 11
Fax: +49 251 788 788 88

DE (MUNSTER) participant 366˙560.00
7    CONSORZIO PER LA RICERCA SUL TRAPIANTO DI ORGANI TESSUTI CELLULE E MEDICINA RIGENERATIVA

 Organization address address: PASSAGIO GAUDENZIO LUIGI 1
city: PADOVA
postcode: 35131

contact info
Titolo: Mr.
Nome: Giovannie
Cognome: Guglielmi
Email: send email
Telefono: +39 049 87 74760
Fax: +39 049 87 85350

IT (PADOVA) participant 357˙760.00
8    THE UNIVERSITY OF MANCHESTER

 Organization address address: OXFORD ROAD
city: MANCHESTER
postcode: M13 9PL

contact info
Titolo: Ms.
Nome: Claire
Cognome: Faichnie
Email: send email
Telefono: +44 161 275 1413

UK (MANCHESTER) participant 338˙863.00
9    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

 Organization address address: SCHLOSSPLATZ 2
city: MUENSTER
postcode: 48149

contact info
Titolo: Mr.
Nome: Ingo
Cognome: Niendorf
Email: send email
Telefono: +49 251 83 55881
Fax: +49 251 83 54035

DE (MUENSTER) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

msn    stem    cell    expertise    neurodegenerative    differentiation    clinical    neural    disease    cells    therapies    primary    point    translation    human    vitro    capacity    hd    trials    gmp    single    fetal   

 Obiettivo del progetto (Objective)

'This project will tackle the huge complexity of taking stem cell therapies to clinical application for neurodegenerative disease by focusing on selective differentiation of a single neuronal phenotype (medium spiny striatal neuron: MSN) for a single well-defined disease (Huntington’s: HD). Our consortium contains expertise in all elements required to drive this technology to the point of clinical delivery, including expertise in stem cell differentiation and control of proliferation; in vitro genetic, molecular, cellular and functional characterisation; preclinical assessment in both rodents and primates models of HD; GMP knowledge, development and production; and clinical translation. Our clinical team includes world leaders in HD clinical trials, including fetal neural transplants and is well placed to design the translation process. We focus on human embryonic stem (hES) cells as our primary target for first-in-man proof-of-concept studies, as they are closest to clinical readiness. HD is the target disease as it provides both an excellent model relevant to a wide range of neurodegenerative conditions, and is a stringent test of the capacity of selectively differentiated stem cells to repair neural circuits. The starting point for the work is the existence within the consortium of three of the most advanced protocols to date for MSN differentiation, and a feature of our consortium is that the specificity of stem cell differentiation will be tested against primary fetal MSNs (current gold standard) at all stages of both in vitro and in vivo assessment. In order to maintain flexibility in an emerging ethical environment, we will develop induced pluripotent (hiPS) cells to the point of GMP validation as a second generation target to hESCs. This will build European infrastructure and capacity to deliver emergent stem cell therapies through the highest quality clinical trials into clinical practice in a broad range of human neurodegenerative diseases.'

Altri progetti dello stesso programma (FP7-HEALTH)

MM4TB (2011)

More Medicines for Tuberculosis

Read More  

RD-CONNECT (2012)

"RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research"

Read More  

CBHI INDIA (2009)

Developing efficient and responsive community based micro health insurance in India

Read More